GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:GSK
  • CUSIP: N/A
  • Web:
  • Market Cap: $99.55 billion
  • Outstanding Shares: 2,443,000,000
Average Prices:
  • 50 Day Moving Avg: $43.02
  • 200 Day Moving Avg: $41.78
  • 52 Week Range: $37.20 - $45.58
  • Trailing P/E Ratio: 45.58
  • Foreward P/E Ratio: 14.20
  • P/E Growth: 1.16
Sales & Book Value:
  • Annual Revenue: $38.07 billion
  • Price / Sales: 2.61
  • Book Value: $0.92 per share
  • Price / Book: 44.29
  • Annual Dividend: $1.94
  • Dividend Yield: 4.7%
  • EBIDTA: $9.57 billion
  • Net Margins: 5.48%
  • Return on Equity: 113.31%
  • Return on Assets: 9.03%
  • Debt-to-Equity Ratio: 2.61%
  • Current Ratio: 0.89%
  • Quick Ratio: 0.61%
  • Average Volume: 2.77 million shs.
  • Beta: 1.04
  • Short Ratio: 1.71
Frequently Asked Questions for GlaxoSmithKline PLC (NYSE:GSK)

What is GlaxoSmithKline PLC's stock symbol?

GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?

GlaxoSmithKline PLC declared a quarterly dividend on Wednesday, July 26th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.491 per share on Thursday, October 12th. This represents a $1.96 annualized dividend and a dividend yield of 4.82%. The ex-dividend date is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. View GlaxoSmithKline PLC's Dividend History.

How were GlaxoSmithKline PLC's earnings last quarter?

GlaxoSmithKline PLC (NYSE:GSK) announced its earnings results on Wednesday, July, 26th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. View GlaxoSmithKline PLC's Earnings History.

Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?

18 analysts have issued 1-year target prices for GlaxoSmithKline PLC's shares. Their forecasts range from $37.00 to $50.00. On average, they expect GlaxoSmithKline PLC's stock price to reach $45.67 in the next twelve months. View Analyst Ratings for GlaxoSmithKline PLC.

Who are some of GlaxoSmithKline PLC's key competitors?

Who are GlaxoSmithKline PLC's key executives?

GlaxoSmithKline PLC's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer - Designate, Executive Director
  • Simon Dingemans, Chief Financial Officer, Executive Director
  • Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
  • Roger Connor, President - Global Manufacturing & Supply
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E Troy, Senior Vice President, General Counsel
  • Claire Thomas, Senior Vice President - Human Resources
  • Nick Hirons, Senior Vice President – Global Ethics and Compliance

Who owns GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.51%), Confluence Investment Management LLC (0.08%), RE Advisers Corp (0.08%), Hamlin Capital Management LLC (0.07%), Miller Howard Investments Inc. NY (0.07%) and Kornitzer Capital Management Inc. KS (0.05%). View Institutional Ownership Trends for GlaxoSmithKline PLC.

Who sold GlaxoSmithKline PLC stock? Who is selling GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was sold by a variety of institutional investors in the last quarter, including Miller Howard Investments Inc. NY, US Bancorp DE, Jarislowsky Fraser Ltd, Kornitzer Capital Management Inc. KS, P.A.W. Capital Corp, Janney Capital Management LLC, Prospera Financial Services Inc and Atria Investments LLC. View Insider Buying and Selling for GlaxoSmithKline PLC.

Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Confluence Investment Management LLC, Aperio Group LLC, GW&K Investment Management LLC, Bank of Montreal Can, John G Ullman & Associates Inc., Honkamp Krueger Financial Services Inc. and Beacon Financial Group. View Insider Buying and Selling for GlaxoSmithKline PLC.

How do I buy GlaxoSmithKline PLC stock?

Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline PLC's stock price today?

One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $40.75.

MarketBeat Community Rating for GlaxoSmithKline PLC (NYSE GSK)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  604 (Vote Underperform)
Total Votes:  891
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $45.67 (12.07% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Citigroup Inc.Reiterated RatingNeutralLowView Rating Details
7/24/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageEqual WeightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
10/20/2016InvestecInitiated CoverageBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
9/20/2016Bank of America CorporationReiterated RatingBuy$50.00N/AView Rating Details
9/12/2016HSBC Holdings plcReiterated RatingBuyN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
8/12/2016ArgusBoost Price TargetBuy$48.00 -> $50.00N/AView Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00N/AView Rating Details
11/6/2015Morgan StanleyReiterated RatingNeutralN/AView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellN/AView Rating Details
10/20/2015Credit Suisse GroupUpgradeUnderperform -> NeutralN/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for GlaxoSmithKline PLC (NYSE:GSK)
Earnings by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Earnings History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
2017 EPS Consensus Estimate: $2.89
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.59$0.63$0.61
Q2 20171$0.71$0.71$0.71
Q3 20171$0.83$0.83$0.83
Q4 20171$0.74$0.74$0.74
(Data provided by Zacks Investment Research)


Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
Next Dividend:10/12/2017
Annual Dividend:$1.94
Dividend Yield:4.76%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:233.74% (Trailing 12 Months of Earnings)
67.83% (Based on This Year's Estimates)
67.60% (Based on Next Year's Estimates)
Dividend Payments by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Dividend History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline PLC (NYSE:GSK)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 8.98%
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlaxoSmithKline PLC (NYSE:GSK)
Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
DateHeadline logoOverhaul Drug R&D? Easier Said Than Done - July 27 at 7:48 PM logoGlaxoSmithKline Capital Inc. -- Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings - July 27 at 7:48 PM logoGlaxoSmithKline PLC's (NYSE:GSK) "Neutral" Rating Reiterated at Citigroup Inc. - July 27 at 2:05 PM logoGlaxoSmithKline PLC (NYSE:GSK) Plans Dividend Increase - $0.49 Per Share - July 27 at 11:17 AM logoDrugmaker GSK calls for at least two years' Brexit transition - July 27 at 5:54 AM logoGlaxo CFO Says Prioritizing R&D for Product Growth - July 27 at 5:54 AM logoGlaxo Looks Beyond the Lab - July 27 at 5:54 AM logoGSK gives up on rare diseases as gene therapy gets two customers - July 27 at 5:54 AM logoGlaxoSmithKline is Now Oversold (GSK) - Nasdaq - July 26 at 7:50 PM logoGlaxo reports 2Q loss - July 26 at 7:50 PM logo[$$] Glaxo Slashes R&D Projects to Focus on Top Prospects - July 26 at 7:50 PM logo$9.52 Billion in Sales Expected for GlaxoSmithKline PLC (GSK) This Quarter - July 26 at 12:01 PM logoAnalysts’ Recommendations for Merck in July 2017 - July 25 at 7:34 PM logoCorporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma - July 25 at 7:34 PM logoGSK hires ex-Wal-Mart executive to transform tech operations - July 25 at 7:34 PM logoGlaxoSmithKline Names Former Walmart Exec as New CTO - July 25 at 7:34 PM logoViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings - July 25 at 7:34 PM logoInside GlaxoSmithKline’s 2Q17 Earnings Estimates - July 25 at 7:33 PM logoUnpacking GlaxoSmithKline’s 2Q17 Revenue Expectations - July 25 at 7:33 PM logoGSK-backed ViiV Healthcare pushing forward in HIV treatments - July 24 at 9:19 PM logo$0.68 Earnings Per Share Expected for GlaxoSmithKline PLC (GSK) This Quarter - July 24 at 4:28 PM logoJ P Morgan Chase & Co Reaffirms Neutral Rating for GlaxoSmithKline PLC (GSK) - July 24 at 12:00 PM logoBRIEF-GSK and Innoviva submit EU filing for extended use of Relvar Ellipta - July 22 at 1:13 AM logoGlaxoSmithKline PLC (NYSE:GSK) Stock Rating Lowered by Zacks Investment Research - July 21 at 9:30 AM logoWhat Lies in Store for Glaxo (GSK) this Earnings Season? - Nasdaq - July 20 at 8:12 PM logoEmergent Inks Agreement to Acquire Anthrax Drug Raxibacumab - July 20 at 8:12 PM logoTOP NEWS: GSK To Make More Medicines In UK, But Less Consumer Goods - July 20 at 5:57 AM
News IconBRIEF-GSK to sell UK Horlicks business - July 20 at 5:57 AM logoGlaxoSmithKline to Sell Its U.K. Horlicks Brand - July 20 at 5:57 AM logoGlaxoSmithKline to sell its UK Horlicks brand - July 19 at 7:54 PM logoGSK puts old antibiotics and UK Horlicks business on the block - July 19 at 7:54 PM logo[$$] GlaxoSmithKline to Sell Its U.K. Horlicks Brand - July 19 at 7:54 PM logoZacks Investment Research Upgrades GlaxoSmithKline plc (GSK) to "Buy" - July 18 at 8:32 PM logoJefferies Group Research Analysts Raise Earnings Estimates for GlaxoSmithKline PLC (GSK) - July 17 at 10:14 AM logoGlaxoSmithKline PLC (NYSE:GSK) Receives Average Rating of "Hold" from Analysts - July 14 at 8:22 PM logoGSK September 1st Options Begin Trading - Nasdaq - July 14 at 2:39 AM logoGlaxoSmithKline PLC (GSK) Rating Reiterated by J P Morgan Chase & Co - July 13 at 3:34 PM logoGlaxoSmithKline PLC (GSK) Downgraded by Citigroup Inc. - July 9 at 9:40 PM logoGlaxoSmithKline’s Performance in 2Q17 - July 8 at 11:12 AM logoHead-To-Head Analysis: Aralez Pharmaceuticals (ARLZ) & GlaxoSmithKline PLC (GSK) - July 8 at 7:36 AM logoHealthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks - July 5 at 7:52 PM logoNovartis Gets EC Nod for Lung Cancer Drug's Label Expansion - Nasdaq - June 29 at 11:29 PM logoGlaxoSmithKline Begins Mepolizumab Phase III Study - Quick Facts - June 27 at 5:46 PM logoGSK's new CEO aims to divest sports nutrition brand: sources - Reuters - June 23 at 2:32 AM logoGSK's new CEO aims to divest sports nutrition brand: sources - June 23 at 2:32 AM logoGSK Wins $235 Million From Teva in Coreg Patent Trial - New York Times - June 21 at 7:13 PM logoGSK wins $235 million from Teva in Coreg patent trial - June 21 at 7:13 PM logoDupixent May Prove Effective in Multiple Diseases - June 20 at 6:21 PM logoGlaxoSmithKline PLC (GSK) Given Average Rating of "Buy" by Analysts - June 19 at 9:16 PM logoGlaxoSmithKline's Benlysta Positive in Continuation Trial - Nasdaq - June 19 at 12:47 PM



GlaxoSmithKline PLC (GSK) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff